

# Index

**ABBREVIATED BIOLOGICS LICENSE APPLICATIONS (aBLAs)**  
Generally, § 3:3, 3:6 to 3:14  
Better than reference product, consequences, § 3:10  
BPCIA, jurisdiction before submission of aBLA, § 4:1  
Clinical trials, § 3:8  
Demonstrating biosimilarity requirements, § 3:6 to 3:11  
Exclusivity, interchangeable product, § 3:12  
Interchangeability, demonstrating, § 3:11, 3:12  
Labeling requirements for biosimilar and interchangeable biosimilar products, § 3:13  
Manufacturing information, § 3:7  
No patent linkage, § 3:14  
Proving biosimilarity, § 3:9  
Reference product, consequences of comparison, § 3:10  
Worse than reference product, consequences, § 3:10

**ANTICIPATION**  
Validity, ineligible subject matter, § 4:82

**ANTITRUST ACTIONS**  
Generally, § 8:1 to 8:6  
Acquisition and enforcement of intellectual property patent thickets, § 8:5  
sham litigation, § 8:4  
walker process fraud, § 8:4  
Challenges to patent settlement agreements, § 8:2  
Enforcement. Acquisition and enforcement of intellectual

**ANTITRUST ACTIONS—Cont'd**  
property, above  
Exclusionary contracting and rebating strategies, § 8:6  
Filing agreements with government, § 8:3

**APPEALS**  
Post-grant proceedings, § 5:20

**APPLICATION TYPES**  
Abbreviated Biologics License Applications (aBLAs), § 3:3  
Approved NDAs for biological products, deemed to be BLAs, § 3:5  
Biologics License Applications (BLAs), § 3:2  
Drug products not regulated as biological products, § 3:4

**APPROVAL**  
FDA Approval (this index)

**APPROVED (NDAs) FOR BIOLOGICAL PRODUCTS, DEEMED TO BE (BLAs)**  
NDAs to BLAs, conversion, § 3:5

**ATTORNEYS' FEES**  
Remedies, enforceability of patent, § 4:96

**BIOBETTERS**  
Generally, § 3:15

**BIOLOGICS LICENSE APPLICATIONS (BLAs)**  
Generally, § 3:2

**BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCIA)**  
Generally, § 2:1, 4:1 to 4:98

<b>BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCIA)</b>	<b>COMMENCEMENT OF SUIT</b>
<b>—Cont'd</b>	<b>—Cont'd</b>
Discovery	Limitation on claims—Cont'd
generally, <b>§ 4:61 to 4:68</b>	scope-limiting ability of applicant, <b>§ 4:53</b>
confidence tiers, <b>§ 4:68</b>	second wave litigation, <b>§ 4:54</b>
expedited discovery, <b>§ 4:64</b>	Standing, <b>§ 4:42</b>
manufacturing information, <b>§ 4:62</b>	Venue (this index)
overlapping patents-in-suit, <b>§ 4:63</b>	
preliminary injunction, <b>§ 4:64</b>	<b>CONFIDENTIAL INFORMATION</b>
prosecution bars, <b>§ 4:66</b>	Patent Dance (this index)
protective orders, <b>§ 4:65 to 4:68</b>	Protective orders, confidentiality tiers, <b>§ 4:68</b>
regulatory bars, <b>§ 4:67</b>	
same biological product, <b>§ 4:63</b>	
Newly issued or licensed patents, <b>§ 4:21</b>	<b>CONSTRUCTION</b>
Notice of Commercial Marketing (NCM) (this index)	Patent infringement liability, claim construction, <b>§ 4:70</b>
Patent Dance (this index)	
Patent Infringement Liability (this index)	<b>CONTINUED PROSECUTION</b>
Post-Grant Proceedings (this index)	Prosecution of biologic patents, <b>§ 1:10</b>
Preliminary injunctions, <b>§ 4:58, 4:64</b>	
Remedies (this index)	<b>COUNTERCLAIMS</b>
Scheduling, staging and consolidation, <b>§ 4:59</b>	Reference product sponsor (RPS), right to bring declaratory judgment action, <b>§ 4:49</b>
Scheduling and staging, <b>§ 4:60</b>	
<b>CITIZEN PETITIONS</b>	<b>DECLARATORY JUDGMENT ACTION</b>
FDA approval process, <b>§ 3:23</b>	Reference product sponsor (RPS), right to bring
<b>COMMENCEMENT OF SUIT</b>	262(l)(9)(A), <b>§ 4:46</b>
Generally, <b>§ 4:32 to 4:57</b>	262(l)(9)(B), <b>§ 4:45</b>
Declaratory Judgment Action (this index)	262(l)(9)(C), <b>§ 4:44 to 4:46</b>
Jurisdiction (this index)	generally, <b>§ 4:43 to 4:50</b>
Jury Trial (this index)	counterclaims, application to, <b>§ 4:49</b>
Limitation on claims	discretionary exercise of declaratory judgment jurisdiction, <b>§ 4:50</b>
generally, <b>§ 4:51 to 4:54</b>	limits on ability of applicants to seek declaratory relief, <b>§ 4:47</b>
failure of applicant to provide notice, <b>§ 4:52</b>	non-jurisdictional treatment by courts, <b>§ 4:48</b>
first wave litigation, <b>§ 4:53</b>	timing of suit, <b>§ 4:46</b>
	Venue, <b>§ 4:37 to 4:39</b>

## INDEX

### DISCOVERY

Biologics Price Competition and Innovation Act (BPCIA) (this index)  
Foreign litigation  
    generally, **§ 7:1 to 7:4**  
    discretion, **§ 7:4**  
    ex parte application, **§ 7:3**  
    Section 1782 Action, **§ 7:2 to 7:4**

### DOCTRINE OF EQUIVALENTS

Patent infringement liability, direct infringement, **§ 4:76**

### DOUBLE PATENTING

Obviousness-type, **§ 4:85**

### ENFORCEMENT AND ENFORCEABILITY

Antitrust Actions (this index)  
Intellectual property acquisition and enforcement. Antitrust Actions (this index)  
NCM provisions, **§ 4:26**  
Patent dance, confidential information, **§ 4:13**  
Patent Infringement Liability (this index)  
Remedies (this index)

### ENSNAREMENT

Patent infringement liability, direct infringement, **§ 4:78**

### ESTOPPEL

Generally, **§ 5:13 to 5:16**  
Patent infringement liability, prosecution history estoppel, **§ 4:77**  
Patent owner estoppel, **§ 5:16**  
Real parties in interest and privity, **§ 5:14**  
Scope of estoppel, **§ 5:15**

### EXCLUSIVITY

FDA approval process, provisions impacting biosimilars, **§ 3:17 to 3:20**

### EX PARTE APPLICATION

Discovery, foreign litigation, **§ 7:3**

### FDA APPROVAL

Generally, **§ 3:1**  
Application Types (this index)  
Process  
    generally, **§ 3:16 to 3:24**  
    citizen petitions, **§ 3:23**  
    complete response letters, **§ 3:24**  
    exclusivity provisions impacting biosimilars, **§ 3:17 to 3:20**  
    Licensure, conditions of use, licensed reference product, **§ 3:21**  
    naming, **§ 3:22**  
    orphan drug exclusivity, **§ 3:20**  
    pediatric exclusivity, **§ 3:19**  
    reference product exclusivity, **§ 3:18**  
    review timeline, **§ 3:16 to 3:24**

### FIRST WAVE LITIGATION

Commencement of suit, limitation on claims, **§ 4:53**  
Patent dance, **§ 4:19, 4:20**

### FOREIGN MATTERS

Discovery in the US for use in foreign litigation. Discovery (this index)  
International Trade Commission (ITC) (this index)  
Patent infringement liability, products manufactured abroad using domestically patented process, **§ 4:75**  
Venue, foreign defendants, **§ 4:36**

### FRAUD

Antitrust actions, intellectual property acquisition and enforcement, walker process, **§ 8:4**

### INJUNCTIONS

Permanent injunctive relief, **§ 4:97**

**INJUNCTIONS—Cont'd**

Preliminary Injunctions (this index)

**INSPECTIONS**

Post-licensure requirements, establishment inspection, **§ 3:25**

**INTERCHANGEABILITY**

Abbreviated biologics license applications (aBLAs), **§ 3:11, 3:12**

**INTERNATIONAL TRADE COMMISSION (ITC)**

Comparison between Section 337 investigations and district court litigations, **§ 6:4**  
Elements of Section 337 violation, **§ 6:2**  
Remedies, **§ 6:3**  
Section 337 actions, **§ 6:1 to 6:4**

**JOINDER**

Post-grant proceedings, **§ 5:18**

**JURISDICTION**

Discretionary exercise of declaratory judgment jurisdiction, **§ 4:50**  
Personal, **§ 4:41**  
Product liability claims, primary jurisdiction, **§ 9:5**  
Subject matter, **§ 4:40**

**JURY TRIAL**

Generally, **§ 4:55 to 4:57**  
Biosimilar v. biosimilar patent cases, **§ 4:57**  
BPCIA cases, **§ 4:56**  
Right to, **§ 4:55 to 4:57**

**LABELING**

Product liability claims, FDA biosimilar labeling, **§ 9:2**

**LICENSURE**

Fda approval process, conditions of use, licensed reference product, **§ 3:21**

**MANUFACTURING**

Abbreviated biologics license applications (aBLAs), manufacturing information, **§ 3:7**

BPCIA, discovery, manufacturing information, **§ 4:62**  
Product liability claims, manufacturing defect claims, **§ 9:3**

**MANUFACTURING PATENTS**

Prosecution of biologic patents, **§ 1:4**

**MARKET EXCLUSIVITY**

Prosecution of biologic patents, BPCIA, **§ 1:2**

**MOTIONS**

Stay, **§ 5:12**

**NAMES AND NAMING**

FDA approval process, **§ 3:22**

**NEGOTIATION**

Patent dance, **§ 4:19, 4:20**

**NOTICE OF COMMERCIAL MARKETING (NCM)**

Generally, **§ 4:22 to 4:31**  
Second wave litigation generally, **§ 4:28 to 4:31**  
appearance of, **§ 4:31**  
factors impacting bringing suit after NCM provided, **§ 4:30**  
who can bring suit after applicant provides NCM, **§ 4:29**  
Statute governing NCM generally, **§ 4:23 to 4:27**  
enforcement of NCM provisions, **§ 4:26**  
requirements for providing NCM, **§ 4:25**  
timing of NCM, **§ 4:24**  
Timing of NCM, **§ 4:24**

## INDEX

**OBVIOUSNESS**  
Double patenting, obviousness-type, **§ 4:85**  
Ineligible subject matter, **§ 4:83**  
Validity, **§ 4:83, 4:85**

**ORPHAN DRUGS**  
FDA approval process, orphan drug exclusivity, **§ 3:20**

**PATENT DANCE**  
3A statement, **§ 4:14**  
3B statement by biosimilar applicant  
generally, **§ 4:15 to 4:17**  
detailed statement, **§ 4:17**  
list, **§ 4:16**  
3C statement by RPS, **§ 4:18**  
Generally, **§ 4:2 to 4:20**  
Confidential information, protection  
generally, **§ 4:8 to 4:13**  
enforceability, **§ 4:13**  
prosecution bar, **§ 4:10**  
recipients of confidential information, **§ 4:9 to 4:11**  
regulatory bar, **§ 4:11**  
use during and after patent dance, **§ 4:12**  
Disclosure of product information to RPS  
generally, **§ 4:3 to 4:7**  
additional requested information, **§ 4:7**  
consequences of failure to provide, **§ 4:6**  
copy of aBLA, **§ 4:4**  
“such other information,” **§ 4:5**  
First wave of litigation, **§ 4:19, 4:20**  
Negotiation, **§ 4:19, 4:20**  
Reference product sponsor (RPS)  
disclosure of product information to RPS, above statements, **§ 4:14, 4:18**  
Unenforceability allegations, **§ 4:88, 4:89**

**PATENT INFRINGEMENT**  
Prosecution of biologic patents, BPCIA, **§ 1:1**

**PATENT INFRINGEMENT LIABILITY**  
Generally, **§ 4:69 to 4:79**  
Claim construction, **§ 4:70**  
Direct infringement, literal, **§ 4:71**  
Doctrine of equivalents, **§ 4:76**  
Enforceability  
generally, **§ 4:86 to 4:89**  
inequitable conduct, **§ 4:88**  
unclean hands, **§ 4:87**  
unenforceability allegations in BPCIA patent dance, **§ 4:89**  
Ensnarement, **§ 4:78**  
Indirect infringement  
generally, **§ 4:72 to 4:78**  
contributory infringement, **§ 4:74**  
doctrine of equivalents, **§ 4:76**  
ensnarement, **§ 4:78**  
induced infringement, **§ 4:73**  
products manufactured abroad using domestically patented process, **§ 4:75**  
prosecution history estoppel, **§ 4:77**  
safe harbor, **§ 4:79**  
Literal direct infringement, **§ 4:71**  
Safe harbor, **§ 4:79**  
Validity of patent. Validity (this index)

**PEDIATRICS**  
FDA approval process, pediatric exclusivity, **§ 3:19**

**POST-GRANT PROCEEDINGS**  
Generally, **§ 5:1 to 5:20**  
Appeals, **§ 5:20**  
Estoppel (this index)  
Joinder, **§ 5:18**  
Parallel post-grant proceedings and BPCIA litigations, **§ 5:3**  
Serial petitions, **§ 5:19**

**POST-GRANT PROCEEDINGS**

—Cont’d

Settlement, **§ 5:17**

Stays (this index)

**POST-LICENSURE REQUIREMENTS**

Additional requirements, **§ 3:28**

Establishment inspection, **§ 3:25**

Product changes, **§ 3:26**

Promotional labeling and advertising considerations for prescription biological reference, biosimilar and interchangeable biosimilar products, **§ 3:27**

**PREEMPTION**

Product liability claims, field preemption, **§ 9:5**

**PRELIMINARY INJUNCTIONS**

Generally, **§ 4:58**

Expedited discovery, **§ 4:64**

**PRODUCT LIABILITY CLAIMS**

Generally, **§ 9:1 to 9:5**

Failure to warn claims, **§ 9:1**

Field preemption, **§ 9:5**

Labeling, FDA biosimilar labeling, **§ 9:2**

Manufacturing defect claims, **§ 9:3**

Primary jurisdiction, **§ 9:5**

Product design defect claims, **§ 9:4**

**PROSECUTION OF BIOLOGIC PATENTS**

Generally, **§ 1:1 to 1:11**

Biosimilars, patent term extension, **§ 1:11**

Continued prosecution, **§ 1:10**

Enablement, section 112, **§ 1:7**

Manufacturing patents, method of, **§ 1:4**

Nonobviousness, section 103, **§ 1:6**

Novelty, section 102, **§ 1:5**

**PROSECUTION OF BIOLOGIC PATENTS—Cont’d**

Overlap with market exclusivity, BPCIA, **§ 1:2**

Patent infringement under, BPCIA, **§ 1:1**

Protection to pursue, scope of, **§ 1:3**

Support for antibody patents, section 112, **§ 1:9**

Written description, section 112, **§ 1:8**

**PROTECTIVE ORDERS**

Generally, **§ 4:65 to 4:68**

Confidentiality tiers, **§ 4:68**

Prosecution bars, **§ 4:66**

Regulatory bars, **§ 4:67**

**REFERENCE PRODUCTS**

Abbreviated biologics license applications (aBLAs), consequences of comparison, **§ 3:10**

FDA approval process, reference product exclusivity, **§ 3:18**

Reference product sponsor (RPS)

Declaratory Judgment Action (this index)

Patent Dance (this index)

**REMEDIES**

Generally, **§ 4:90 to 4:98**

Conforming amendments of BPCIA, **§ 4:91**

Delaying effective date of FDA approval, **§ 4:92**

Enforceability of patent

at-risk launch, **§ 4:95**

attorneys' fees, **§ 4:96**

monetary damages, **§ 4:94, 4:95**

pre-market activity, **§ 4:94**

safe harbor, **§ 4:94**

Injunctions (this index)

ITC remedies, **§ 6:3**

Limitations on remedies, **§ 4:98**

Monetary damages, enforceability of patent, **§ 4:94, 4:95**

## INDEX

<b>REMEDIES—Cont'd</b>	
Monetary relief, § 4:93 to 4:95	
Settlement of BPCIA litigation, § 4:99	
<b>SAFE HARBOR</b>	
Patent infringement liability, § 4:79	
Remedies, enforceability of patent, § 4:94	
<b>SECOND WAVE LITIGATION</b>	
Commencement of suit, limitation on claims, § 4:54	
Notice of Commercial Marketing (NCM) (this index)	
<b>SERIAL PETITIONS</b>	
Post-grant proceedings, § 5:19	
<b>SETTLEMENT</b>	
Antitrust actions, challenges to patent settlement agreements, § 8:2	
Post-grant proceedings, § 5:17	
<b>STANDING</b>	
Commencement of suit, § 4:42	
<b>STAYS</b>	
Generally, § 5:4 to 5:11	
Motions to stay, § 5:12	
Simplification of issues, § 5:6	
Stage of litigation, § 5:5	
Undue prejudice	
generally, § 5:7 to 5:11	
relationship of parties, § 5:11	
review request, timing, § 5:8	
status of review proceedings, § 5:10	
stay request, timing, § 5:9	
<b>TIME AND TIMING</b>	
Declaratory judgment action, right of RPS to bring, § 4:46	
FDA approval process, review timeline, § 3:16 to 3:24	
Notice of commercial marketing (NCM), timing of, § 4:24	
<b>TIME AND TIMING—Cont'd</b>	
Remedies, delaying effective date of FDA approval, § 4:92	
Review request, timing, § 5:8	
Scheduling, staging and consolidation, BPCIA, § 4:59	
Scheduling and staging, § 4:60	
Stay request, timing, § 5:9	
<b>TRIALS</b>	
Biologics license applications (BLAs), abbreviated applications, § 3:8	
<b>UNCLEAN HANDS</b>	
Patent infringement liability, enforceability, § 4:87	
<b>VALIDITY</b>	
Generally, § 4:80 to 4:85	
Enablement, lack of, § 4:84	
Indefiniteness, § 4:84	
Ineligible subject matter	
generally, § 4:81 to 4:83	
anticipation, § 4:82	
obviousness, § 4:83	
Obviousness-type double patenting, § 4:85	
Written description, lack of, § 4:84	
<b>VENUE</b>	
Generally, § 4:32 to 4:39	
Declaratory judgment, § 4:37 to 4:39	
Patent infringement actions	
generally, § 4:33 to 4:36	
declaratory judgment, § 4:38, 4:39	
defendant's residence, § 4:34	
foreign defendants, § 4:36	
infringement, § 4:35	
place of business, § 4:35	
<b>WRITTEN DESCRIPTION</b>	
Validity, lack of written description, § 4:84	